Mergers & Acquisitions ·
On August 10, 2026, Jazz Pharmaceuticals plc announced it has entered into a definitive Agreement and Plan of Merger…
JAZZJazz Pharmaceuticals plc
On August 10, 2026, Jazz Pharmaceuticals plc announced it has entered into a definitive Agreement and Plan of Merger to acquire Actio Biosciences, Inc. The transaction values the acquisition at an initial Aggregate Upfront Transaction Value of $820 million, adjusted for cash, indebtedness, and transaction expenses. Shareholders will receive this value on a fully diluted per-share basis. Additionally, holders are entitled to contingent milestone payments totaling up to $500 million, including a $250 million development milestone upon regulatory approval for ABS-1230 for KCNT1-Related Epilepsy, and sales milestones of $100 million and $150 million at $500 million and $1 billion in annual net sales, respectively. The deal requires the completion of a spin-out transaction separating non-ABS-1230 programs into a new entity called SpinCo, where Jazz will hold a minority stake. Closing is subject to customary conditions, including HSR Act clearance and 85% stockholder approval from Actio Biosciences. Jazz Pharmaceuticals plc operates in the biopharmaceutical industry, focusing on the development and commercialization of medicines for serious neurological disorders.